A Phase 2, Randomized, Open-Label Trial to Describe the Safety and Immunogenicity of a Monovalent Pneumococcal Conjugate Candidate Administered As a 2-Dose Series in Healthy Toddlers 11 Through 15 Months of Age Who Previously Received the PCV10 Primary Series
Latest Information Update: 10 May 2025
At a glance
- Drugs Monovalent-pneumococcal-conjugate-vaccine-Pfizer (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 03 Jun 2024 Status changed from active, no longer recruiting to completed.
- 20 Feb 2024 Planned End Date changed from 29 May 2024 to 30 May 2024.
- 20 Feb 2024 Planned primary completion date changed from 29 May 2024 to 30 May 2024.